Loading clinical trials...
Loading clinical trials...
A Two-Part 1b/2a Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy
Conditions
Interventions
CNP-201
Placebo
Locations
9
United States
Medical Research of Arizona
Scottsdale, Arizona, United States
Stanford University School of Medicine / Sean N. Parker Center for Allergy and Asthma Research
Mountain View, California, United States
Peninsula Research Institute
Rolling Hills Estates, California, United States
Allergy & Asthma Medical Group and Research Center
San Diego, California, United States
Allergy & Asthma Associates of Santa Clara Valley Research Center
San Jose, California, United States
Pharmaceutical Research & Consulting, Inc
Dallas, Texas, United States
Start Date
June 2, 2021
Primary Completion Date
June 24, 2022
Completion Date
July 29, 2022
Last Updated
September 18, 2023
NCT03835767
NCT04222491
NCT04511494
NCT03881696
NCT07117669
NCT03859700
Lead Sponsor
COUR Pharmaceutical Development Company, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions